Skip to main content
×
Home

EMEA and the evaluation of health-related quality of life data in the drug regulatory process

  • Sotiria Papanicolaou (a1), David Sykes (a1) and Elias Mossialos (a2)
Abstract

Objectives: This study reviewed the European guidelines of the Committee for Proprietary Medicinal Products (CPMP) on how health-related quality of life (HRQOL) research should be conducted in clinical trials. Published product-level information was also reviewed to investigate the actual role of HRQOL data in the European regulatory process.

Methods: All disease-specific notes for guidance and concept papers on clinical investigations, development and evaluation of human medicinal products, as well as the European Public Assessment Reports (EPAR) of all approved drugs published on the European Agency for the Evaluation of Medicinal Products (EMEA) Web site were evaluated for their HRQOL recommendations.

Results: Only twenty of the fifty CPMP guidance notes for clinical investigation of pharmaceutical products in specific disease areas included a reference to HRQOL. Most of the recommendations were generic and vague, and the terminology used was inconsistent across documents. The EPAR provided nonspecific information about HRQOL and contradictory conclusions on the effect of a drug on HRQOL sometimes occurred in different documents. The criteria used by the CPMP to assess the HRQOL data could not be identified due to an ad hoc approach to the inclusion of data in the EPAR.

Conclusions: A more systematic approach is needed on the way health outcomes data are considered, reviewed, and interpreted by the regulatory authorities. For this to be achieved, CPMP should develop general guidelines on the importance of HRQOL and how research should be conducted if data are to be included in the registration process.

Copyright
References
Hide All
Apolone G, De Carli G, Brunetti M, Garattini S. 2001 Health-related quality of life (HR-QOL) and regulatory issues. Pharmacoeconomics. 19: 187195.
Bech P. 1992 Issues of concern in the standardization and harmonization of drug trials in Europe: Health-related quality of life, ESCT meeting, Strasbourg, May 23–24, 1991. Qual Life Res. 1: 143145.
Burke LB. 2001 US regulation of pharmaceutical outcomes research. Value Health. 4: 57.
Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. 2002 Patient-reported outcomes: The example of health-related quality of life—a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information J. 36: 209238
Corcos J, Beaulieu S, Donovan J, Naughton M, Gotoh M, and members of the symptom and quality of life assessment committee of the first international consultation on incontinence. 2002 Quality of life assessment in men and women with urinary incontinence. J Urol. 168: 896905.
Dowie J. 2002 Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions. Health Econ. 11: 18.
EMEA. Note for guidance on antiarrhythmics (CPMP/EWP/237/95) 1995. Available at: http://www.emea.eu.int/pdfs/human/ewp/023795en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on the clinical investigation of anti-anginal medicinal products used in stable angina pectoris (CPMP/EWP/234/95) 1996. Available at: http://www.emea.eu.int/pdfs/human/ewp/023495en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on medical products in the treatment of Altzheimer's disease (CPMP/EWP/553/95) 1997. Available at: http://www.emea.eu.int/pdfs/human/ewp/055395en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on the clinical investigation of drugs used in weight control (CPMP/EWP/281/96) 1997. Available at: http://www.emea.eu.int/pdfs/human/ewp/028196en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on the clinical investigation of medicinal products for the treatment of Parkinson's disease (CPMP/EWP/563/95) 1998. Available at: http://www.emea.eu.int/pdfs/human/ewp/056395en.pdf. Accessed: March 13, 2003.
EMEA. ICH Topic E9. Statistical principles for clinical trials (CPMP/ICH/363/96) 1998. Available at: http://www.emea.eu.int/pdfs/human/ich/036396en.pdf. Accessed: March 13, 2003.
EMEA. Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis (CPMP/EWP/784/97) 1998. Available at: http://www.emea.eu.int/pdfs/human/ewp/078497en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on the clinical investigation of medicinal products for the treatment of cardiac failure (CPMP/EWP/235/95) 1999. Available at: http://www.emea.eu.int/pdfs/human/ewp/023595en.pdf. Accessed: March 13, 2003.
EMEA. Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD) (CPMP/EWP/562/98) 1999. Available at: http://www.emea.eu.int/pdfs/human/ewp/056298en.pdf. Accessed: March 13, 2003.
EMEA. Points to consider on clinical investigation of medicinal products for the treatment of amylotrophic lateral sclerosis (CPMP/EWP/565/98) 2000. Available at: http://www.emea.eu.int/pdfs/human/ewp/056598en.pdf. Accessed: March 13, 2003.
EMEA. Points to consider on clinical investigation of medicinal products for the management of Crohn's disease (CPMP/EWP/2284/99) 2001. Available at: http://www.emea.eu.int/pdfs/human/ewp/228499en.pdf. Accessed: March 13, 2003.
EMEA. Points to consider on the clinical investigation of medicinal products for the treatment of acute stroke (CPMP/EWP/560/98) 2001. Available at: http://www.emea.eu.int/pdfs/human/ewp/056098en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on the clinical investigation of medicinal products for the treatment of multiple sclerosis (CPMP/EWP/561/98) 2001. Available at: http://www.emea.eu.int/pdfs/human/ewp/056198en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on the clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease (CPMP/EWP/714/98) 2002. Available at: http://www.emea.eu.int/pdfs/human/ewp/071498en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on evaluation of anticancer medicinal products in man (CPMP/EWP/205/96) 2002. Available at: http://www.emea.eu.int/pdfs/human/ewp/020595en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on the clinical investigation of medicinal products for the treatment of asthma (CPMP/EWP/2922/01) 2002. Available at: http://www.emea.eu.int/pdfs/human/ewp/292201en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on the clinical investigation of medicinal products for the treatment of Urinary Incontinence (CPMP/EWP/18/01) 2002. Available at: http://www.emea.eu.int/pdfs/human/ewp/001801en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on clinical investigation of medicinal products for the treatment of migraine (CPMP/EWP/778/01 draft) 2002. Available at: http://www.emea.eu.int/pdfs/human/ewp/078801en.pdf. Accessed: March 13, 2003.
EMEA. Points to consider on clinical investigation of medicinal products for treatment of rheumatoid arthritis (CPMP/EWP/556/95 draft) 2002. Available at: http://www.emea.eu.int/pdfs/human/ewp/055695en.pdf. Accessed: March 13, 2003.
EMEA. Note for guidance on the clinical development of medicinal products for treatment of HIV infection (CPMP/EWP/778/01) 2003. Available at: http://www.emea.eu.int/pdfs/human/ewp/063302en.pdf. Accessed: March 13, 2003.
EMEA. Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome (CPMP/EWP/785/97) 2003. Available at: http://www.emea.eu.int/pdfs/human/ewp/078597en.pdf. Accessed: March 13, 2003.
Fantoni M, Izzi I, Del Borgo C, et al. 1999 Inter-rater reliability of a modified Karnofsky scale of performance status for HIV-infected individuals. AIDS Patient Care STDS. 13: 2328.
Fayers P, Bottomley A. 2002 Quality of life research within the EORTC—the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 38 (Suppl 4): S125S133.
FDA, Division of Drug Marketing, Advertising and Communications (DDMAC). Policy development and guidance to industry. Available at: http://www.fda.gov/cder/handbook/pol_guid.htm. Accessed: June 6, 2003).
Feeny D. 2002 Commentary on Jack Dowie, “Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions.” Health Econ. 11: 1316.
Frost MH, Sloan JA. 2002 Quality of life measurements: A soft outcome—or is it? Am J Manag Care. 8 (Suppl): S574S579.
Guyatt G. 2002 Commentary on Jack Dowie, “Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions.” Health Econ. 11: 912.
Guyatt GH, Jaeschke RJ. 1997 Reassessing quality-of-life instruments in the evaluation of new drugs. Pharmacoeconomics. 12: 621626.
Lee CW, Chi KNJ. 2000 The standard of reporting of health-related quality of life in clinical cancer trials. Clin Epidemiol. 53: 451458.
Leidy NK, Revicki DA, Geneste B. 1999 Recommendations for evaluating the validity of quality of life claims for labelling and promotion. Value Health 2: 113127.
Montazeri A, McEwen J, Gillis CR. 1996 Quality of life in patients with ovarian cancer: Current state of research. Support Care Cancer. 4: 169179.
Neymark N, Kiebert W, Torfs K, et al. 1998 Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: Report of a workshop. Eur J Cancer. 34: 13171333.
National Institute for Clinical Excellence (1999). Guidance for manufacturers and sponsors. Available at: http://www.nice.org.uk/pdf/technicalguidanceformanufacturersandsponsors.pdf. Accessed: March 13, 2003.
O'Donnell P. 2002 European regulatory agencies. Applied Clin Trials. 3637.
Radensky P. 2001 Regulation of pharmacoeconomics and outcomes research. Value Health. 4: 1215.
Revicki DA, Ehreth JL. 1997 Health-related quality-of-life assessment and planning for the pharmaceutical industry. Clin Ther. 19: 11011115.
Revicki DA, Osoba D, Fairclough D, et al. 2000 Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 9: 887900.
Revicki DA, Rothman M, Luce B. 1992 Health-related quality of life assessment and the pharmaceutical industry. Pharmacoeconomics. 1: 394408.
Rogers SN, Gwanne S, Lowe D, et al. 2002 The addition of mood and anxiety domains to the University of Washington quality of life scale. Head Neck. 24: 521529.
Santanello NC, Baker DB, Cappelleri JC, et al. 2002 Regulatory issues for health-related quality of life-PhRMA Health Outcomes Committee Workshop, 1999. Value Health. 5: 1425.
Sloan JA, Cella D, Frost M, et al. 2002 Clinical Significance Consensus Meeting Group. Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc. 77: 367370.
Symonds T, Berzon R, Marquis P, Rummans TA. 2002 The clinical significance of quality-of-life results: Practical considerations for specific audiences. Clinical Significance Consensus Meeting Group. Mayo Clin Proc. 77: 572583.
Trask PC, Paterson AG, Wang C, et al. 2001 Cancer-specific worry interference in women attending a breast and ovarian cancer risk evaluation program: Impact on emotional distress and health functioning. Psychooncology. 10: 349360.
Wu AW, Revicki DA, Jacobson D, Malitz FE. 1997 Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 6: 481493.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 2
Total number of PDF views: 3 *
Loading metrics...

Abstract views

Total abstract views: 50 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 12th December 2017. This data will be updated every 24 hours.